Clinical Oncology
Volume 20, Issue 2 , Pages 152-156 , March 2008

Vinorelbine and Infusional 5-fluorouracil in Anthracycline and Taxane Pre-treated Metastatic Breast Cancer

  • N.S.A. Stuart

      Affiliations

    • Alaw Unit, Ysbyty Gwynedd, Bangor, Gwynedd LL57 2PW, UK
    • Corresponding Author InformationAuthor for correspondence: N. S. A. Stuart, Alaw Unit, Ysbyty Gwynedd, Bangor, Gwynedd LL57 2PW, UK. Tel: +44-1248-384150; Fax: +44-1248-384505.
    • ,
  • M.B. McIllmurray

      Affiliations

    • Oncology Department, Royal Lancaster Infirmary, Ashton Road, Lancaster LA1 4KP, UK
    • ,
  • J.L. Bishop

      Affiliations

    • Alaw Unit, Ysbyty Gwynedd, Bangor, Gwynedd LL57 2PW, UK
    • ,
  • S.R.D. Johnston

      Affiliations

    • Department of Medical Oncology, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    • ,
  • C.G.A. Price

      Affiliations

    • Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8ED, UK
    • ,
  • S.M. O'Reilly

      Affiliations

    • Clatterbridge Centre for Oncology, Clatterbridge Road, Bebbington, Merseyside CH63 4JY, UK
    • ,
  • J.K. Joffe

      Affiliations

    • Greenlea Oncology Unit (Ward 3), Huddersfield Royal Infirmary, Lindley, Huddersfield HD3 3EA, UK
    • ,
  • F. Neave

      Affiliations

    • Department of Oncology, North Middlesex Hospital, Sterling Way, London N18 1QX, UK
    • ,
  • E.C. Whipp

      Affiliations

    • Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8ED, UK

Received 27 June 2006 ,Revised 26 September 2007 ,Accepted 30 October 2007.

References 

  1. MacMillan WE, Wolberg WH, Welling PG. Pharmacokinetics of fluorouracil in humans. Cancer Res. 1978;38(10):3479–3482
  2. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15(2):808–815
  3. Chang AY, Most C, Pandya KJ. Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol. 1989;12(5):453–455
  4. Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. J Infus Chemother. 1996;6(4):211–216
  5. Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol. 1996;7(8):807–813
  6. Ross P, Norman A, Cunningham D, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin-C in advanced colorectal cancer. Ann Oncol. 1997;8:995–1001
  7. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT vs intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38(3):349–358
  8. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17(2):239–245
  9. Crawford J, O'Rouke M, Schiller J, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol. 1996;14:2774–2784
  10. Gregory RK, Smith IE. Vinorelbine–a clinical review. Br J Cancer. 2000;82(12):1907–1913
  11. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13–47
  12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214
  13. Dieras V, Extra JM, Bellissant E, et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol. 1996;14(12):3097–3104
  14. Nole F, de Braud F, Aapro M, et al. Phase I–II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol. 1997;8(9):865–870
  15. Berruti A, Sperone P, Bottini A, et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol. 2000;18(19):3370–3377
  16. Lombardi D, Magri MD, Crivellari D, et al. Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Ann Oncol. 2000;11(8):1041–1043
  17. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812–2823
  18. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588–592
  19. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993;11(7):1245–1252
  20. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994;5(9):854–857
  21. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92(9):2267–2272
  22. Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15(4):1395–1400
  23. Toi M, Saeki T, Aogi K, et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol. 2005;35(6):310–315

PII: S0936-6555(07)00875-8

doi: 10.1016/j.clon.2007.10.013

Clinical Oncology
Volume 20, Issue 2 , Pages 152-156 , March 2008

Article Tools

* Image Usage & Resolution